Michael Higgins

Michael J.
Higgins is Chief Executive Officer & Director at KinDex Pharmaceuticals, Inc. since 2015.
Holds the position of Chairman at Voyager Therapeutics, Inc. since 2022 and at Pulmatrix, Inc. since 2020.
Serves as Director at Morgan Stanley Private Equity Access Fund II LP and Private Equity Access Fund II.
Director at Sea Pharmaceuticals LLC and Madauder Therapeutics, Inc. since 2016.
Independent Director at Cyclerion Therapeutics, Inc. since 2023 and at Nocion Therapeutics, Inc. since 2020.
Formerly Director at Pulmatrix Operating Co., Inc. in 2015, Microbia, Inc., and Ruthigen, Inc. Independent Director at Genocea Biosciences, Inc. from 2015 to 2022 and at CAMP4 Therapeutics Corp.
from 2017 to 2026.
Vice President-Corporate Finance & Business Development at Genzyme Corp.
from 1997 to 2003.
Chief Operating Officer at Ironwood Pharmaceuticals, Inc. in 2014.
Chief Financial Officer at Procept, Inc. from 1992 to 1997 and at Boston Business Journal.
Education includes undergraduate degree from Cornell University and MBA from Tuck School of Business at Dartmouth.